09.03.2018
To the attention of interested persons
Press release: EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta.
NAMMD mention: Zinbryta (daclizumab) is not marketed in Romania on publication of this press release.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002920.jsp&mid=WC0b01ac058004d5c1